A lot of things that seem on first glance to be “news” are really just reprints or slight edits of press releases written to tout a commercial product. This is also true of “Newsletters” that charge money for inside news.
Datamonitor is a company that claims to be “the world’s leading provider of online data, analytic and forecasting platforms for key vertical sectors. We help 5,000 of the world’s largest companies profit from better, more timely decisions” (Datamonitor website). Some of the stuff they give away, since I see it and I don’t subscribe to anything they sell. But based on its accuracy, I don’t have much confidence in their premium products. Consider the “news” item about a TB test being marketed by a company called Cellestis. The headline says that the Cellestis TB test has been found effective in a landmark study:
Cellestis International has reported positive results from a landmark study that showed QuantiFERON-TB Gold, a blood test for detecting TB infection, six times more accurate than the conventional tuberculin skin test or TST at predicting which tuberculosis-exposed individuals will go on to develop TB disease.
The results demonstrated from the study indicated that QFT had a predictive value for developing TB disease of 15%, more than 6 times greater than the 2.3% for the TST. (Datamonitor)
Predictive value (which comes in two forms, not one) is not a measure of accuracy because it depends on two other, real measures of accuracy, sensitivity and specificity, together with the prevalence of the condition in the specific population being tested. It is therefore essentially worthless as an accuracy measure, or at best, hard to compare with other methods. There are many ways positive predictive value can be boosted, some of which aren’t very helpful to the patient or the provider.
These kinds of test kits aren’t new, either. So this is just PR. Pure, unadulterated PR. If that’s what the Datamonitor product is, why would anyone pay for it? Just asking.